Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
bluebird bio (BLUE)
NASDAQ:BLUE
Holding BLUE?
Track your performance easily
BLUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.80 - $38.38
Previous CloseN/A
Volume68.97K
Average Volume (3M)583.98K
Market Cap
$82.25M
Enterprise Value$390.74M
Total Cash (Recent Filing)$704.38M
Total Debt (Recent Filing)$120.14M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Feb 25, 2025EPS Estimate
-5.75Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)-35.97
Shares Outstanding9,722,217
10 Day Avg. Volume301,557
30 Day Avg. Volume583,975
Standard Deviation0.22
R-Squared0.03
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.65
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap4.75
Enterprise Value/Revenue7.36
Enterprise Value/Gross Profit-96.96
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$38.00Price Target Upside349.17% Upside
Rating ConsensusHold
Number of Analyst Covering8
Bluebird Bio News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe approved 1-for-20 reverse stock split increased the price target significantly.
Market ExpansionBLUE has activated more than 70 QTCs for Zynteglo and Lyfgenia, indicating a broader treatment reach.
Product DemandA recent ramp in sales, driven by Lyfgenia uptake, leaves room for substantial future growth.
Bears Say
Cash Flow And Financial HealthThe cash runway is currently a concern, with sufficient funds expected only until the first quarter of next year, which may weigh on the shares until a financial path forward is announced.
Financial Performance3Q24 revenue of $10.6mm was below the expected $21.1mm and continues to decline sequentially QoQ from $16.1mm in 2Q24 and $18.6mm in 1Q24.
Product Safety ConcernsHigher risk findings are expected to hinder further uptake of the ex-vivo genetic cell therapy Skysona.
---
Ownership Overview
Currently, No data available
---
BLUE FAQ
What was bluebird bio’s price range in the past 12 months?
bluebird bio lowest stock price was $5.80 and its highest was $38.38 in the past 12 months.
What is bluebird bio’s market cap?
bluebird bio’s market cap is $82.25M.
When is bluebird bio’s upcoming earnings report date?
bluebird bio’s upcoming earnings report date is Feb 25, 2025 which is in 46 days.
How were bluebird bio’s earnings last quarter?
bluebird bio released its earnings results on Nov 14, 2024. The company reported -$6.2 earnings per share for the quarter, beating the consensus estimate of -$7.283 by $1.083.
Is bluebird bio overvalued?
According to Wall Street analysts bluebird bio’s price is currently Undervalued.
Does bluebird bio pay dividends?
bluebird bio pays a Notavailable dividend of $177.66 which represents an annual dividend yield of N/A. See more information on bluebird bio dividends here
What is bluebird bio’s EPS estimate?
bluebird bio’s EPS estimate is -5.75.
How many shares outstanding does bluebird bio have?
bluebird bio has 9,722,217 shares outstanding.
What happened to bluebird bio’s price movement after its last earnings report?
bluebird bio reported an EPS of -$6.2 in its last earnings report, beating expectations of -$7.283. Following the earnings report the stock price went down -3.718%.
Which hedge fund is a major shareholder of bluebird bio?
Among the largest hedge funds holding bluebird bio’s share is Graham Capital Management, L.P.. It holds bluebird bio’s shares valued at 0.
---
Bluebird Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$38.00 (349.17% Upside)
$38.00 (349.17% Upside)
Blogger Sentiment
Bullish
BLUE Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 66.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.22%
12-Months-Change
Fundamentals
Return on Equity
5193.90%
Trailing 12-Months
Asset Growth
-24.21%
Trailing 12-Months
Company Description
bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
---
BLUE Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong patient start growth, successful cost reduction efforts, and promising reimbursement pathways. However, these positives were countered by a decrease in quarterly revenue, cash resource challenges, and pending shareholder approvals, creating a balanced outlook.Read More>---
BLUE Stock 12 Month Forecast
Average Price Target
$38.00
▲(349.17% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Voyager Therapeutics
―
Abeona Therapeutics
―
Best Analysts Covering BLUE
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+13.72%
reiterated a sell rating 8 months ago
Copying Salveen Richter's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +13.72% per trade.
---